ACCESS TO, AND AVAILABILITY OF MEDICINAL PRODUCTS: A POTENTIAL FOR IMPROVEMENT
Airat Farrakhov, Deputy, Deputy Chairman of the Commission of the State Duma of the Federal Assembly of the Russian Federation for Support of the Development of Small- and Medium-sized Business
Elena Maksimkina, Head, Federal State Institution "Federal Center for Planning and Regulation Of Medical Supply Circulation"
Alla Samoylova, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
The recent years’ experience has shown economic feasibility of centralized supply of medicinal products.
Performance-based agreements for new medicines and various innovative procurement arrangements have been applied in all countries with developed health systems since the early 2000s. But, despite the obvious advantages and a number of pilot projects implemented, these new models are not approved at the federal level due to disagreements.
Issues for discussion:
• What are the positive aspects of centralized procurement, what risks are important to foresee when expanding centralized procurement practices?
• Why do European countries unite for joint procurement of medicinal products?
• What needs to be done to benefit from new procurement arrangements?